Abstract
The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols
-
Bacteremia / etiology
-
C-Reactive Protein / metabolism
-
Carmustine
-
Case-Control Studies
-
Cytarabine
-
Etoposide
-
Febrile Neutropenia / etiology
-
Female
-
Fibroblast Growth Factor 7 / therapeutic use*
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Humans
-
Inflammation
-
Intestinal Mucosa / pathology*
-
Male
-
Melphalan
-
Middle Aged
-
Mucositis / drug therapy*
-
Neutropenia
-
Young Adult
Substances
-
Cytarabine
-
Fibroblast Growth Factor 7
-
Etoposide
-
C-Reactive Protein
-
Melphalan
-
Carmustine